Nasdaq
$79.10▼ 1.29%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.77BShares out 60.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
29- 4d agoOvernight26.10.21 09:424Ownership#●●●
Oruka Therapeutics, Inc.
Insider Paul T. Quinlan of Oruka Therapeutics, Inc. filed a Form 4 on October 20, 2026, to report changes in beneficial ownership of securities. This filing serves as an official record of the insider's equity transaction.…more
$79.10-1.29%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15After-hours26.10.16 07:154Ownership
Oruka Therapeutics, Inc.
Insider Joana Goncalves of Oruka Therapeutics, Inc. filed a Form 4 report regarding changes in beneficial ownership of securities on October 15, 2026. This filing serves as an official disclosure of the insider's equity transaction.…more
$79.10-1.29%vs prev closeView filingShare - 10.15After-hours26.10.16 05:38144Ownership
Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. filed a Form 144 on October 15, 2026, regarding a proposed sale of securities by insider Joana Goncalves. This filing serves as a formal notification of the insider's intent to dispose of shares.…more
$79.10-1.29%vs prev closeView filingShare
28 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.23Regular26.09.23 22:49#●●●#●●●
Oruka Therapeutics Reports Positive Phase 2a Results for Psoriasis Drug…more
Oruka Therapeutics announced that its psoriasis candidate ORKA-001 demonstrated deepening efficacy in a Phase 2a trial. The drug maintained a consistent safety profile, with further long-term data expected in 2026.…more
$79.10-1.29%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.23Pre-market26.09.23 20:00
●●●●●●●● ●●●●● ●●●●●●
Oruka Therapeutics announced positive 28-week results from its Phase 2a trial of ORKA-001, showing sustained and deepening clinical responses even after dosing ceased. These findings support the potential for the drug to provide durable disease control with very infrequent administration.…more
$79.10-1.29%vs prev close - 9.9After-hours26.09.10 05:01
●●●●●●●● ●●●●● ●●●●●●
Oruka Therapeutics announced its participation in the 2026 Morgan Stanley Global Healthcare Conference scheduled for September 14-16. This event attendance is a routine corporate update and does not provide immediate material impact on the stock.…more
$79.10-1.29%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report